New Offering Announcement by Inventiva
Daix (France), New York City – Inventiva (NASDAQ: IVA) has officially disclosed the pricing for an upsized public offering of approximately $150 million in American Depositary Shares (ADSs). These shares are designed to represent new ordinary shares of the company.
Details of the Offering
The offering includes 38,961,038 new ADSs priced at $3.85 each. This pricing reflects the volume-weighted average price of the shares on the Euronext Paris for the last trading session before the offering date, with a small discount applied. The anticipated settlement date for this offering is set for November 17, 2025.
Utilization of Proceeds
Inventiva plans to allocate roughly 80% of the offering proceeds to further its ongoing NATiV3 Phase 3 clinical trials, alongside preparations for additional trials and commercialization efforts. The remaining 20% is earmarked for general corporate expenditures and working capital.
Current Financial Position
As of the latest financial reports, Inventiva has approximately €97.6 million in cash and equivalents, along with €24.7 million in short-term deposits. Following the offering, the company projects sufficient funds to support its operations through the beginning of the first quarter of 2027, depending on whether the underwriters' option is exercised.
The Underwriters' Option
The underwriters, specifically Leerink Partners and Piper Sandler, have a 30-day option to acquire up to 5,844,155 additional ADSs, equivalent to 15% of the total offered, further increasing the capital raised under favorable conditions.
Market Impact and Expectations
Piper Sandler will also serve as the stabilization agent, potentially executing transactions to support the market price of the ADSs. However, it is important to note that there are no guarantees regarding the stabilization efforts.
About Inventiva
Inventiva is a clinical-stage biopharmaceutical company focused on developing innovative therapies for metabolic disorders, particularly metabolic dysfunction-associated steatohepatitis (MASH). Its leading asset is lanifibranor, which has shown promise in clinical trials.
Contact Information
For more details, interested investors can contact Inventiva via email at media@inventivapharma.com or call +1 202 499 8937.
Frequently Asked Questions
What is the purpose of this offering?
The offering aims to finance Inventiva's ongoing clinical trials and support its general operational needs.
How much capital does Inventiva expect to raise?
Inventiva anticipates raising approximately $150 million through this offering.
What will the proceeds be used for?
About 80% will fund the NATiV3 clinical trial, while 20% is allocated for working capital and corporate purposes.
Who are the underwriters for this offering?
Leerink Partners and Piper Sandler are managing the underwriting for this public offering.
When is the settlement date for this offering?
The expected settlement date for the offering is November 17, 2025, pending usual closing conditions.
